Volume 13, Number 3—March 2007
Dispatch
Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone
Table
Antimicrobial drug | MIC (μg/mL) and CLSI interpretation | ||
---|---|---|---|
November | February | April | |
Nafcillin | >2 R | 16 R | >2 R |
Clindamycin | 2 I | ≤0.25 S | <0.25 S |
Erythromycin | 4 I | >8 R | >4 R |
Trimethoprim-sulfamethoxazole | <0.5/9.5 S | ≤0.25/5 S | <0.5/9.5 S |
Tetracycline | <1 S | ≤0.5 S† | <1 S |
Rifampin | <1 S | ≤0.25 S | <1 S |
Ciprofloxacin | >2 R | >4 R | >2 R |
Levofloxacin | >4 R | ND | >4 R |
Gentamicin | <1 S | ≤0.5 S | 2 S |
Vancomycin | <2 S | 2 S | 8 I 4–6 I‡ |
Daptomycin | ND | 1 S | 2§ |
Linezolid | ND | 2 S | 2 S |
Tigecycline | ND | 0.125 S | 0.125 S |
*CLSI, Clinical and Laboratory Standards Institute; R, resistant; I, intermediately resistant; S, susceptible; ND, not done.
†Susceptibility to doxycycline performed instead of to tetracycline.
‡Confirmatory susceptibility by E-test and growth on vancomycin (6 µg/mL) agar screen plates.
§Interpreted as nonsusceptible by the Centers for Disease Control and Prevention. Formal CLSI breakpoints for daptomycin resistance have not been established.
Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.